MDCX

Medicus is a clinical-stage, multi-strategy biotech with no product revenue in any year shown (FY2023–FY2025 revenue all blank) and losses that are accelerating violently: net income went -$5.31M → -$11.2M → -$47.3M, a 323.8% YoY deterioration in FY2025. The MD&A confirms the profile — 'we have not generated revenues to date,' 'we cannot predict when, if ever, we will be profitable,' and operating expenses are expected to keep rising as R&D (up 118.9% to $7.72M) and trial costs mount. This is a binary bet on SkinJect's D-MNA microneedle patch for basal cell carcinoma and the newly acquired Teverelix (Antev), not a business with a financial track record to underwrite.

The balance sheet is the disqualifier. Stockholders' equity is negative (-$67.6K) against a -$64.3M accumulated deficit, total liabilities jumped 299% to $10.0M, and the liabilities/equity ratio of -148x is a symptom of insolvency-adjacent capitalization. Most acutely, $8.71M of cash sits against -$22.8M of annual operating cash burn — roughly four to five months of runway — plus $5.25M of current debt due within a year. Funding this company requires near-continuous capital raises, and the market has already felt it: shares outstanding ballooned 193.4% YoY to 39.4M, driving diluted EPS to -$2.74. At $0.42 the stock is a sub-$20M-equity micro-cap that will almost certainly need to dilute again, into an already destroyed cap table.